Postbiotic Innovation — Beyond Probiotics
- October 27, 2025
SporeGen’s postbiotic nasal spray offers a first-in-class approach to respiratory virus protection. With proven efficacy in animal studies and Phase 1 human safety trials complete, our technology is ready for global commercialization.
- Safe & Proven – Phase 1 human trials completed with no safety issues
- Trusted Manufacturing – WHO-GMP manufacturer; non-GMO & no live bacteria
- Regulatory Backing – Accredited cGLP toxicology studies and IP filed (PCT)
- Commercial Footprint – Already sold as a medical device in SE Asia
We are seeking industry partners to advance this breakthrough to global markets.
📩 Contact Dr Simon Cutting – s.cutting@sporegen.com